NASDAQ:EDGE - Edge Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.83 -0.02 (-2.35 %) (As of 10/17/2018 05:42 AM ET)Previous Close$0.85Today's Range$0.83 - $0.8952-Week Range$0.70 - $17.77Volume149,700 shsAverage Volume819,964 shsMarket Capitalization$25.69 millionP/E RatioN/ADividend YieldN/ABeta3.49 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey. Receive EDGE News and Ratings via Email Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:EDGE CUSIPN/A Webwww.edgetherapeutics.com Phone800-208-3343 Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.36 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$2.02 per share Price / Book0.41 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-50,850,000.00 Net MarginsN/A Return on Equity-92.04% Return on Assets-62.19% Miscellaneous Employees38 Outstanding Shares31,330,000Market Cap$25.69 million Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions What is Edge Therapeutics' stock symbol? Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE." How were Edge Therapeutics' earnings last quarter? Edge Therapeutics Inc (NASDAQ:EDGE) released its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.53) by $0.12. View Edge Therapeutics' Earnings History. When is Edge Therapeutics' next earnings date? Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 7th 2018. View Earnings Estimates for Edge Therapeutics. What price target have analysts set for EDGE? 2 brokerages have issued twelve-month price targets for Edge Therapeutics' stock. Their forecasts range from $17.00 to $17.00. On average, they expect Edge Therapeutics' share price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,948.2% from the stock's current price. View Analyst Price Targets for Edge Therapeutics. What is the consensus analysts' recommendation for Edge Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edge Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Edge Therapeutics. Who are some of Edge Therapeutics' key competitors? Some companies that are related to Edge Therapeutics include IMMUTEP LTD/S (IMMP), Vernalis (VNLPY), GT Biopharma (GTBP), BELLUS Health (BLUSF), Northwest Biotherapeutics (NWBO), Arcturus Therapeutics (ARCT), Iterum Therapeutics (ITRM), IntelGenx Technologies (IGXT), Axsome Therapeutics (AXSM), NewLink Genetics (NLNK), Cumberland Pharmaceuticals (CPIX), Proteostasis Therapeutics (PTI), Chiasma (CHMA), Alpine Immune Sciences (ALPN) and Medicure (MCUJF). Who are Edge Therapeutics' key executives? Edge Therapeutics' management team includes the folowing people: Mr. Brian A. Leuthner, Co-Founder, CEO, Pres & Director (Age 53)Dr. R. Loch MacDonald, Co-Founder, Chief Scientific Officer & Director (Age 56)Dr. Herbert J. Faleck, Chief Medical Officer (Age 65)Mr. Andrew Saik, Chief Financial Officer (Age 49)Mr. Albert N. Marchio II, Chief Accounting & Admin. Officer (Age 66) How do I buy shares of Edge Therapeutics? Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Edge Therapeutics' stock price today? One share of EDGE stock can currently be purchased for approximately $0.83. How big of a company is Edge Therapeutics? Edge Therapeutics has a market capitalization of $25.69 million. Edge Therapeutics employs 38 workers across the globe. What is Edge Therapeutics' official website? The official website for Edge Therapeutics is http://www.edgetherapeutics.com. How can I contact Edge Therapeutics? Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected] MarketBeat Community Rating for Edge Therapeutics (NASDAQ EDGE)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 128 (Vote Outperform)Underperform Votes: 134 (Vote Underperform)Total Votes: 262MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe EDGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/17/2018 by MarketBeat.com StaffFeatured Article: How accurate is the Rule of 72?